Sana Biotechnology, Inc. (SANA) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
4.96
↑+58% vs avg
5yr avg: 3.14
30Y Low1.5·High6.4
ROE
↑
-118.7%
-5% vs avg
5yr avg: -113.1%
30Y Low-232%·High-44%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SANA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Sana Biotechnology, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $877M | $1.0B | $376M | $794M | $744M | $2.6B | — | — | — |
| Enterprise Value | $884M | $1.0B | $343M | $764M | $675M | $2.4B | — | — | — |
| P/E Ratio → | -3.28 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 4.96 | 6.41 | 1.50 | 2.76 | 1.49 | 3.54 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
SANA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
SANA Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -118.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -118.7% | -118.7% | -99.2% | -72.0% | -43.9% | -231.6% | — | — | — |
| ROA | -53.2% | -53.2% | -50.0% | -40.8% | -27.6% | -38.3% | -49.8% | -58.2% | -38.6% |
| ROIC | -74.4% | -74.4% | -86.1% | -63.8% | -40.2% | -476.6% | — | — | — |
| ROCE | -48.1% | -48.1% | -57.0% | -48.4% | -31.3% | -41.3% | -29.4% | -65.9% | -25.3% |
SANA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $7M ($79M total debt minus $72M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.49 | 0.49 | 0.38 | 0.36 | 0.22 | 0.15 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.04 | -0.13 | -0.10 | -0.14 | -0.20 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — |
SANA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.89x means Sana Biotechnology, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 3.31x to 1.89x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.89 | 1.89 | 3.54 | 3.31 | 3.99 | 5.62 | 12.22 | 7.47 | 18.26 |
| Quick Ratio | 1.89 | 1.89 | 3.54 | 3.31 | 3.99 | 5.62 | 12.22 | 7.47 | 18.26 |
| Cash Ratio | 1.76 | 1.76 | 3.36 | 3.18 | 3.80 | 5.55 | 12.03 | 7.19 | 17.16 |
| Asset Turnover | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
SANA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Sana Biotechnology, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $253M | $231M | $195M | $188M | $166M | $188M | $187M | $187M |
Peer Comparison
Compare SANA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SANAYou | $877M | -3.3 | — | — | — | — | -118.7% | -74.4% | — |
 FATE | $244M | -1.8 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
 CRSP | $5B | -8.4 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 BEAM | $4B | -42.1 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 EDIT | $263M | -1.5 | — | — | 100.0% | -245.2% | -198.1% | — | — |
 NTLA | $2B | -4.1 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 ALNY | $37B | 119.4 | 65.9 | 79.7 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 IONS | $12B | -31.1 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 RCKT | $366M | -1.7 | — | — | — | — | -60.3% | -62.4% | — |
 SGMO | $75M | -0.4 | — | — | 80.8% | -273.1% | -2891.8% | -5405.6% | — |
 ILMN | $25B | 29.7 | 22.7 | 26.4 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
SANA — Frequently Asked Questions
Quick answers to the most common questions about buying SANA stock.
What is Sana Biotechnology, Inc.'s P/E ratio?
Sana Biotechnology, Inc.'s current P/E ratio is -3.3x. This places it at the 50th percentile of its historical range.
What is Sana Biotechnology, Inc.'s ROE?
Sana Biotechnology, Inc.'s return on equity (ROE) is -118.7%. The historical average is -113.1%.
Is SANA stock overvalued?
Based on historical data, Sana Biotechnology, Inc. is trading at a P/E of -3.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.